The Gill Center for Biomolecular Science and the Department of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana 47405, USA.
J Comp Neurol. 2010 Sep 15;518(18):3848-66. doi: 10.1002/cne.22429.
Cannabinoid receptors and their ligands constitute an endogenous signaling system that is found throughout the body, including the eye. This system can be activated by Delta(9)-tetrahydrocannabinol, a major drug of abuse. Cannabinoids offer considerable therapeutic potential in modulating ocular immune and inflammatory responses and in regulating intraocular pressure. The location of cannabinoid receptor 1 (CB(1)) in the retina is known, but recently a constellation of proteins has been identified that produce and break down endocannabinoids (eCBs) and modulate CB(1) function. Localization of these proteins is critical to defining specific cannabinoid signaling circuitry in the retina. Here we show the localization of diacylglycerol lipase-alpha and -beta (DGLalpha/beta), implicated in the production of the eCB 2-arachidonoyl glycerol (2-AG); monoacylglycerol lipase (MGL) and alpha/beta-hydrolase domain 6 (ABHD6), both implicated in the breakdown of 2-AG; cannabinoid receptor-interacting protein 1a (CRIP1a), a protein that may modulate CB(1) function; and fatty acid amide hydrolase (FAAH) and N-acylethanolamine-hydrolyzing acid amidase (NAAA), which have been shown to break down the eCB anandamide and related acyl amides. Our most prominent finding was that DGLalpha is present in postsynaptic type 1 OFF cone bipolar cells juxtaposed to CB(1)-containing cone photoreceptor terminals. CRIP1a is reliably presynaptic to DGLalpha, consistent with a possible role in cannabinoid signaling, and NAAA is restricted to retinal pigment epithelium, whereas DGLbeta is limited to retinal blood vessels. These results taken together with previous anatomical and functional studies define specific cannabinoid circuitry likely to modulate eCB signaling at the first synapse of the retina as well as in the inner plexiform layer.
大麻素受体及其配体构成了一个内源性信号系统,存在于全身,包括眼睛。这个系统可以被 Delta(9)-四氢大麻酚激活,Delta(9)-四氢大麻酚是一种主要的滥用药物。大麻素在调节眼部免疫和炎症反应以及调节眼内压方面具有相当大的治疗潜力。大麻素受体 1 (CB(1))在视网膜中的位置是已知的,但最近已经确定了一系列蛋白质,这些蛋白质可以产生和分解内源性大麻素 (eCBs),并调节 CB(1)的功能。这些蛋白质的定位对于定义视网膜中特定的大麻素信号通路至关重要。在这里,我们展示了二酰基甘油脂肪酶-α和-β (DGLalpha/beta)的定位,它们与内源性大麻素 2-花生四烯酸甘油 (2-AG)的产生有关;单酰基甘油脂肪酶 (MGL)和 α/β-水解酶结构域 6 (ABHD6),它们都与 2-AG 的分解有关;大麻素受体相互作用蛋白 1a (CRIP1a),一种可能调节 CB(1)功能的蛋白质;以及脂肪酸酰胺水解酶 (FAAH)和 N-酰基乙醇胺水解酸酰胺酶 (NAAA),它们已被证明可以分解内源性大麻素大麻素和相关酰基酰胺。我们最突出的发现是 DGLalpha 存在于与含有 CB(1)的视锥感受器末端相邻的突触后 1 型 OFF 锥体细胞中。CRIP1a 与 DGLalpha 可靠地位于突触前,这与大麻素信号传递中的可能作用一致,而 NAAA 局限于视网膜色素上皮,而 DGLbeta 局限于视网膜血管。这些结果与以前的解剖学和功能研究相结合,定义了特定的大麻素回路,这些回路可能在视网膜的第一个突触以及内丛状层调节内源性大麻素信号传递。